Cargando…
MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer
Docetaxel and cabazitaxel are taxane chemotherapy treatments for metastatic castration-resistant prostate cancer (CRPC). However, therapeutic resistance remains a major issue. MicroRNAs are short non-coding RNAs that can silence multiple genes, regulating several signalling pathways simultaneously....
Autores principales: | Lin, Hui-Ming, Nikolic, Iva, Yang, Jessica, Castillo, Lesley, Deng, Niantao, Chan, Chia-Ling, Yeung, Nicole K., Dodson, Eoin, Elsworth, Benjamin, Spielman, Calan, Lee, Brian Y., Boyer, Zoe, Simpson, Kaylene J., Daly, Roger J., Horvath, Lisa G., Swarbrick, Alexander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5959911/ https://www.ncbi.nlm.nih.gov/pubmed/29777112 http://dx.doi.org/10.1038/s41598-018-26050-y |
Ejemplares similares
-
Discovering cancer vulnerabilities using high-throughput micro-RNA screening
por: Nikolic, Iva, et al.
Publicado: (2017) -
Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer
por: Lin, Hui-Ming, et al.
Publicado: (2017) -
MicroRNA profiling of the pubertal mouse mammary gland identifies miR-184 as a candidate breast tumour suppressor gene
por: Phua, Yu Wei, et al.
Publicado: (2015) -
Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer
por: Lin, H-M, et al.
Publicado: (2014) -
Genome-wide screening identifies cell-cycle control as a synthetic lethal pathway with SRSF2(P95H) mutation
por: Xu, Jane Jialu, et al.
Publicado: (2022)